

Microsatellite Instability and Immunohistochemistry Testing in Cancer

EviCore
By EVERNORTH

-
- This benefit/harm statement only applies to those jurisdictions that do not have Medicare guidance.
 - Based upon the guidelines and evidence provided in the clinical policy, following EviCore's criteria for microsatellite instability and immunohistochemistry testing in cancer will ensure that testing will be available to those members most likely to benefit from the information provided by the assays. For those not meeting criteria, it ensures alternate diagnostic/management strategies are considered. However, it is possible that some members who would benefit from the testing, but do not meet clinical criteria, will not receive an immediate approval for testing.